Solara Active Pharma Q1 FY2027 Net Profit Rises to ₹16.31 Crore

Date: July 23, 2026

Board Meeting Outcomes

The Board of Directors at their meeting held on July 23, 2026 (12:00 PM to 1:05 PM) considered and approved:

Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026
Preparation of financial results on a going concern basis

Financial Results (Consolidated)

Quarterly Performance (₹ in Crores)

| Revenue from operations | 381.60 | 387.29 | 319.15 | 1,368.98 |

| Other income | 2.69 | 4.69 | 0.98 | 6.16 |

| Total income | 384.29 | 391.98 | 320.13 | 1,375.14 |

| Profit before tax | 16.31 | 9.60 | 10.52 | (7.41) |

| Profit for the period | 16.31 | 9.60 | 10.52 | (7.41) |

| Total comprehensive income | 16.26 | 10.10 | 10.51 | (4.56) |

| EPS - Basic (₹) | 3.52 | 2.20 | 2.46 | (1.68) |

| EPS - Diluted (₹) | 3.52 | 2.20 | 2.46 | (1.68) |

Expense Breakdown (₹ in Crores)

Cost of materials consumed: 180.81
Purchases of stock-in-trade: 0.86
Changes in inventories: 14.76
Employee benefits expenses: 56.05
Finance costs: 21.64
Depreciation and amortization: 26.71
Other expenses: 67.15
Total expenses: 367.98

Other Comprehensive Income

Exchange differences on translating foreign operations: (0.05)

Capital Structure

Paid-up equity share capital: ₹48.06 crore (face value ₹10 each)
Other equity excluding non-controlling interests: ₹1,208.37 crore (as of Mar 31, 2026)

Financial Results (Standalone)

Quarterly Performance (₹ in Crores)

| Revenue from operations | 381.60 | 387.29 | 319.15 | 1,368.98 |

| Other income | 1.92 | 4.42 | 0.98 | 5.89 |

| Total income | 383.52 | 391.71 | 320.13 | 1,374.87 |

| Profit before tax | 16.99 | 9.73 | 10.53 | (7.24) |

| Profit for the period | 16.99 | 9.73 | 10.53 | (7.24) |

| Total comprehensive income | 16.99 | 10.44 | 10.53 | (3.97) |

| EPS - Basic (₹) | 3.67 | 2.23 | 2.46 | (1.64) |

| EPS - Diluted (₹) | 3.67 | 2.23 | 2.46 | (1.64) |

Capital Structure

Paid-up equity share capital: ₹48.06 crore
Other equity: ₹1,210.93 crore (as of Mar 31, 2026)

Key Notes and Disclosures

Going Concern Basis

Despite reporting a profit of ₹16.31 crore (consolidated) and ₹16.99 crore (standalone) for the quarter ended June 30, 2026, the company has accumulated losses of ₹286.21 crore (consolidated) and ₹285.73 crore (standalone) as of June 30, 2026. The Board has approved preparation of financial results on a going concern basis based on:

Confidence in renewal of working capital facilities
Expectation of increased revenues and margins
Adequate cash inflows from operations to meet future obligations

Rights Issue Progress

The company has raised ₹442.73 crore out of the total rights issue size of ₹449.95 crore through:

Application money received: ₹157.48 crore
First call (May 6, 2025): ₹155.31 crore received (₹2.18 crore unpaid)
Final call (May 7, 2026): ₹129.94 crore received (₹5.04 crore unpaid)

Proceeds are held in bank accounts pending deployment as per Letter of Offer.

Demerger Plans

The Board granted in-principle approval on January 24, 2025 to explore demerger of CRAMS and Polymers business into an independent listed entity. Subsequently, the company incorporated Synthix Global Pharma Solutions Limited as a wholly owned subsidiary on April 29, 2025.

Segment Information

The Group's operations relate to only one reportable segment: Active Pharmaceutical Ingredient (API).

Subsidiaries Included in Consolidation

1. Solara Active Pharma Sciences Limited (Parent)

2. Shasun USA Inc. (wholly owned subsidiary)

3. Chemsvnth Laboratories Private Limited (subsidiary)

4. Synthix Global Pharma Solutions Limited (wholly owned subsidiary)

Exceptional Items

For the quarter ended March 31, 2026, the company recorded an exceptional item profit of ₹0.86 crore related to Gratuity and Compensated absences impact under new labour codes.